DEA plans Epidiolex, allowing GW Pharma to start selling the drug

The Drug Enforcement Administration reprogrammed Epidiolex, paving the way for GW Pharmaceuticals to sell the first FDA-approved drug derived from cannabis, but not allowing reclassification of all cannabidiol-based products.

Source link